Opinion|Videos|December 29, 2025
Switching Therapies, Managing Adverse Effects, and Adherence Challenges
Panelists discuss how balancing adverse-effect management with adherence optimization drives effective therapy transitions.
Advertisement
Episodes in this series
Panelists discuss how therapy switching is often required to optimize outcomes, especially when adverse effects compromise adherence or efficacy wanes over time.
Panelists discuss how neurologic, metabolic, and cardiovascular adverse effects demand vigilant management to prevent treatment discontinuation.
Panelists discuss how adherence remains a linchpin of success, with behavioral and digital interventions offering promising tools to support patient engagement.
Advertisement
Related to this article
Hiddo Heerspink, PhD, discusses finerenone data in type 1 diabetes, FSGS and IgA nephropathy, and open questions on sequencing CKD therapies.
Insmed launches once-daily brensocatib in Japan, the country's only approved treatment for noncystic fibrosis bronchiectasis.
Cross-ancestry GWAS of more than 1.8 million people flags SERPINA1, SMAD3, and other bronchiectasis targets shared with COPD and chronic bronchitis.
The FDA approved bepirovirsen, the first antisense oligonucleotide for chronic hepatitis B, offering a new treatment with functional cure potential.
ALIS added to azithromycin and ethambutol raised culture conversion in new MAC lung disease, with rare resistance, in an ENCORE analysis at IDWeek 2026.
Advertisement
Advertisement
Trending on AJMC
1
Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%
2
Real-World AMKD Data Highlight Quick Progression, Unmet Needs
3
Insurance Barriers Tied to Missed Long-Acting PrEP Starts
4
IDWeek Studies Tie RSV, Flu, and COVID-19 to Harm After Acute Illness
5